The Little White Bag From the Pharmacy That Used to Cost Almost Nothing

The Errand That Took Ten Minutes

Somewhere in the early 1970s, an American with high blood pressure walked into a neighborhood drugstore, handed a slip of paper to the pharmacist, waited a few minutes, and paid about two dollars for a month's supply of medication. He probably didn't think much about it. It was about as financially significant as buying a loaf of bread.

That transaction — unremarkable, routine, barely worth remembering — is now almost impossible to recreate. The medication might be the same. The pharmacy might still be on the same corner. But the price, the paperwork, and the anxiety surrounding it have transformed almost beyond recognition.

When Prescriptions Were Just Part of the Grocery Run

Pharmaceutical pricing in mid-20th century America was, by today's standards, almost disarmingly simple. Drug companies priced medications to be profitable, pharmacies marked them up modestly, and most people paid out of pocket without much drama. Prices were low enough that insurance coverage for prescriptions wasn't even considered essential — it was a secondary concern, if it crossed anyone's mind at all.

Penicillin, introduced commercially in the 1940s, cost the equivalent of a few dollars per course of treatment within a decade of its launch. Insulin, first available in 1923, was famously sold by its Canadian inventors for one dollar each — symbolically, to make clear it should be accessible to everyone who needed it. The idea that a life-sustaining medication might one day cost an American family hundreds of dollars per month would have seemed not just unlikely, but morally absurd.

Through the 1960s and much of the 1970s, that baseline held reasonably well. Prescriptions were affordable. Pharmacists knew their customers. And the concept of rationing your medication because you couldn't afford a full month's supply wasn't part of the American health conversation.

The Numbers That Tell the Story

The contrast between then and now becomes visceral when you look at specific medications.

Take insulin. In 1996, a vial of Humalog — a fast-acting insulin that became standard care for millions of Americans with diabetes — launched at around $21. By 2019, that same vial cost over $275. The medication hadn't changed. The manufacturing process had actually become more efficient. What changed was the pricing environment surrounding it.

Or consider Lipitor, the cholesterol-lowering statin that became one of the best-selling drugs in history. When it launched in 1997, it was priced at roughly $3 per pill. At its peak branded price before generic competition arrived, it was closer to $5 or $6 per pill — and for patients without adequate coverage, that added up fast.

EpiPens tell perhaps the most dramatic story. In 2007, a two-pack cost around $100. By 2016, the price had climbed to over $600 — a 500 percent increase for a device that had existed in essentially the same form for decades. The public outcry was enormous, but the price had already reshaped how many families thought about keeping one on hand.

How the System Changed Around the Medicine

The pharmaceutical pricing system in the United States is genuinely unlike anything else in the developed world, and it didn't get this way by accident.

Several forces converged over the past forty years. Drug companies gained longer and more aggressive patent protections, delaying generic competition. Direct-to-consumer advertising — banned until 1997 — created brand demand that supported premium pricing. The middlemen who negotiate between manufacturers and insurers, known as pharmacy benefit managers, created a rebate system so complex that even industry insiders struggle to explain where money actually flows. And unlike virtually every other wealthy nation, the United States never established a federal mechanism for negotiating drug prices — a gap that manufacturers have used to remarkable effect.

The result is a country where the same medication can cost ten to twenty times more than it does in Canada, Germany, or Australia. Not because the drug is different. Because the pricing system is.

The Human Math

The statistics on what this means for real Americans are sobering. Around 30 percent of adults report not taking medication as prescribed because of cost — skipping doses, cutting pills in half, or simply not filling prescriptions. For people managing chronic conditions like diabetes, hypertension, or heart disease, those decisions have direct health consequences.

The pharmacy counter has become, for many Americans, a place of low-grade dread. You hand over your insurance card and wait to see what the system says you owe today — because the answer changes depending on where you are in your deductible cycle, whether your insurer approved the medication, and whether the manufacturer is currently offering a coupon program to offset the price they set in the first place.

None of that complexity existed when the man with high blood pressure handed two dollars across the counter in 1972.

What We Stopped Expecting

Maybe the most telling shift isn't in the prices themselves — it's in what Americans have stopped expecting. A generation ago, affordable medication was simply assumed. It wasn't a political issue or a campaign talking point. It was just how things worked.

Today, medication affordability ranks consistently among the top financial concerns for American households, sitting alongside housing costs and healthcare premiums. The little white bag from the pharmacy — once the most forgettable errand of the week — has become, for many families, something they budget for carefully, worry about, and sometimes go without.

Before you arrived, it wasn't always this complicated. And understanding how it got this way is the first step toward imagining something different.